Edwards Lifesciences
409 hedge funds and large institutions have $6.58B invested in Edwards Lifesciences in 2013 Q3 according to their latest regulatory filings, with 76 funds opening new positions, 141 increasing their positions, 126 reducing their positions, and 38 closing their positions.
107% more call options, than puts
Call options by funds: $133M | Put options by funds: $64M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
100% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 38
12% more repeat investments, than reductions
Existing positions increased: 141 | Existing positions reduced: 126
9% more funds holding
Funds holding: 375 → 409 (+34)
4% less capital invested
Capital invested by funds: $6.87B → $6.58B (-$289M)
37.68% less ownership
Funds ownership: 543.89% → 506.22% (-38%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$81.9M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$72.3M |
| 3 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$40.5M |
| 4 |
Two Sigma Investments
New York
|
+$38.3M |
| 5 |
HM
HealthCor Management
New York
|
+$35.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$531M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$333M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$118M |
| 4 |
MAA
Managed Account Advisors
Jersey City,
New Jersey
|
-$64.1M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$57.2M |
EW Hedge Fund Activity: Q3 2013 in Review
409 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2013, worth a combined $6.58B — down 4.2% from $6.87B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new EW positions and 38 closed out — a net gain of 38 holders — while 141 added to existing stakes and 126 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $81.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $531M.
- 409 institutional investors held Edwards Lifesciences (EW) as of Q3 2013, up from 375 in Q2 2013.
- Funds reported $6.58B of Edwards Lifesciences stock for Q3 2013, down 4.2% quarter-over-quarter.
- 76 funds opened new Edwards Lifesciences positions in Q3 2013 and 38 closed out, a net change of +38 holders.
- The largest Edwards Lifesciences buyer in Q3 2013 was Goldman Sachs, an estimated $81.9M added.
- The largest Edwards Lifesciences seller in Q3 2013 was T. Rowe Price Associates, an estimated $531M sold.
Based on aggregated 13F filings for Q3 2013.